Organon (OGN) said Tuesday that the US Food and Drug Administration has extended its review of the company's supplemental new drug application for VTAMA cream to treat atopic dermatitis in children at least two years old and adults.
The extended review postpones the target action date to March 12, 2025 from the original target action date of Dec. 12, according to the company.
With the new target action date, Organon said it expects about $125 million revenue contribution from VTAMA and an about 75 basis point headwind to adjusted EBITDA margin in 2025.
Organon said the FDA extended the review period after determining that a major amendment to the supplemental new drug application is required based on additional information submitted by the company.
The FDA did not raise any safety and efficacy concerns, Organon added.
Organon shares were 4.5% lower in recent trading.
Price: 16.16, Change: -0.76, Percent Change: -4.49
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。